Abstract:Introduction: Slow progress in drug development is an ongoing issue even more critical for oncologic drugs, which have lower likelihood for approval than other therapeutic areas. Early clinical trials are frequently conducted and few eventually lead to drug approvals. We analyzed success rates of anti-leukemic drugs presented at the annual ASH meetings to identify rates of progression to advanced development and factors associated with clinical trial (CT) success. Methods: Our eligibility criteria included ASH meetings abstracts reporting CT assessing investigational anti-leukemic drugs conducted in the United States from 2011 to 2015. We searched ClinicalTrials.gov, PubMed, and Food and Drug Administration (FDA) websites to track the transition at each clinical phase (from Phase 1 to Phase 3), regulatory history, and publication as full-length manuscripts. We assessed the success rate (number of CT approved by FDA divided by the total number of CT) by study, drug and outcomes features using chi-square or Fisher's exact test. To verify the correlation between the impact factor (IF) of the journal in which the CT was published with the success of the study, the FDA-approval status (No vs Yes) was considered ordinal variable and the Pearson correlation coefficient was calculated. Results: Among the 3,929 abstracts for leukemia reviewed, 488 were main CT reports. Based on our eligibility criteria, 235 abstracts were identified including Phase 1 (121), Phase 2 (100), and Phase 3 (14) CT. Of these CT abstracts, only 45 (19.1%) eventually led to FDA approval. Among the unsuccessful studies, 37 (15.7%) progressed to the next one or two phases, and 153 (65.1%) did not transition any phase forward. Abstracts in acute myeloid leukemia (AML, 47%) and chronic lymphocytic leukemia (CLL, 30.2%) were the most common, followed by acute lymphocytic leukemia (ALL, 15.6%) and chronic myeloid leukemia (CML, 6.5%). Investigational New Drug (IND) combined with FDA-approved regimens (41.7%) or as monotherapy (40.9%) were the most commonly investigated therapy modalities. Combinations of multiple IND (9.8%) and new uses for FDA-approved drugs or regimens (7.7%) were evaluated less frequently. The overall success rate of CT was 6%. Although CML and ALL were the least studied types of leukemia, they had the highest approval success rates, 47% and 24.4%, respectively (p<0.001). Monotherapy INDs were more frequently approved by FDA (32.3%) than when combined with FDA-approved drugs (11.2%, p<0.001). FDA approval was also more frequent for advanced CT phase (p<0.001) and more recent (by year) presentation of the abstract (p=0.008). Tumor status (untreated vs relapsed and/or refractory [R/R] vs untreated and R/R) and the age of the patients included in the CT (adults including older adults vs older adults only vs pediatric vs adults and pediatric) were not significantly associated with approval rates (p>0.05). CT including drugs and regimens that led to FDA approval were published in journals with higher impact factors (R=0.368, p=0.0002), such as Lancet Oncology (24.1%), Blood (17.2%), Lancet Haematology (13.8%), and New England Journal of Medicine (13.8%). Blood was the journal that published the highest number of unsuccessful CT (15.3%). During the study period, CT assessing Enasidenib as monotherapy for R/R AML with IDH2 mutation, Ponatinib for CML and Philadelphia chromosome (Ph+) ALL, and Venetoclax for R/R CLL transitioned directly from Phase 2 to FDA approval. Conclusion: CT success rates for hematologic malignancies improved modestly over the last years. The high investment in CT for AML and CLL management has not resulted in increased approval rates proportional to reported CT.

Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer.

Lenvatinib Plus PD-1 Inhibitors As First-Line Treatment in Patients with Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial

Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers

Lenvatinib for Hepatocellular Carcinoma: A Literature Review

Novel Insights into Post-Marketing Adverse Events Associated with Lenvatinib: A Comprehensive Analysis Utilizing the FAERS Database

Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer

Outcomes of Phase Ii Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non-Small Cell Lung Cancer Published Between 2000 and 2009

Real-world safety and effectiveness of lenvatinib in unresectable hepatocellular carcinoma in Korea: post-marketing study

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

Real-World Effectiveness of First Line Lenvatinib Therapy in Advanced Hepatocellular Carcinoma: Current Insights

Drug Development for Leukemia : Comprehensive Analysis of Clinical Trial Success Rates Presented at the American Society Hematology (ASH) Annual Meetings

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)

Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity

Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).

Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT

Histology-specific clinical trial of lenvatinib and pembrolizumab in patients with sarcoma

Overview of lenvatinib as a targeted therapy for advanced hepatocellular carcinoma

The dose-optimisation of lenvatinb for patients with unresectable hepatocellular carcinoma in clinical practice: A retrospective analysis of real-world evidence in China.

Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis